Cleerly has raised $106 million in a Series C extension funding round.
The company said it will use the investments for commercial growth and clinical evidence generation around its AI-enabled CT technologies that have been cleared by the U.S. Food and Drug Administration (FDA).
Cleerly’s software is designed to identify heart disease by analyzing noninvasive images. In the announcement, James Min, MD, founder and CEO, noted recent achievements in attaining Medicare coverage and a Current Procedural Terminology (CPT) Category I code for coronary plaque analysis.
The funding round was led by global software investor Insight Partners and joined by Battery Ventures, with participation from preexisting investors, Cleerly said.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
